Medication info

Dihydrazine Plus Tablet

Prescription medicationApproval withdrawn
Ingredient · strength
Losartan Potassium›Strength being verifiedHydrochlorothiazide›Strength being verified
Manufacturer / importer
Daihwa Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
10 tablets/blister x 3, 300 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 200701452 · Notified 2007.02.01

This product's status changed to Approval withdrawn on 2023.06.08. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who uses it
Adults · Children
Adult dosage
○ Adults The usual dose of this medicine is 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. In general, the maximum blood pressure-lowering effect occurs approximately 3 weeks after the start of treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, initiate treatment with this medicine when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Initiate treatment with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Initiate treatment with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control with this dose: Treatment may be initiated with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the dose of hydrochlorothiazide without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or more. Administration is not recommended in patients with more severe renal impairment, because a loop diuretic is preferable to a thiazide-type drug in these patients. ○ Patients with hepatic impairment Administration is not recommended in patients with hepatic impairment requiring dose adjustment, because the initial dose of losartan potassium of 25 mg for these patients cannot be provided with this medicine.
Children's dosage
○ Children (under 18 years of age) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Daihwa Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication can be used to manage blood pressure more effectively in patients with hypertension who are not sufficiently controlled with monotherapy. Since hypertension requires continuous treatment to prevent cardiovascular complications, this medication helps improve blood pressure control.

Dosage and Administration

Adult dosage

○ Adults The usual dose of this medicine is 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. In general, the maximum blood pressure-lowering effect occurs approximately 3 weeks after the start of treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, initiate treatment with this medicine when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Initiate treatment with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Initiate treatment with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control with this dose: Treatment may be initiated with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the dose of hydrochlorothiazide without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or more. Administration is not recommended in patients with more severe renal impairment, because a loop diuretic is preferable to a thiazide-type drug in these patients. ○ Patients with hepatic impairment Administration is not recommended in patients with hepatic impairment requiring dose adjustment, because the initial dose of losartan potassium of 25 mg for these patients cannot be provided with this medicine.

Children's dosage

○ Children (under 18 years of age) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious injury or death to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. This medication should not be used in patients with specific diseases or conditions, such as anuria, severe liver impairment, severe kidney impairment, pregnant women or women of childbearing potential, and patients with certain genetic metabolic disorders. Use with caution in patients with various health conditions, such as hypotension, decreased kidney function, liver impairment, cerebrovascular disorders, and electrolyte imbalances, particularly in elderly patients or those with a history of diabetes or gout who require special attention. During treatment with this medication, regular monitoring of blood pressure, kidney function, and electrolyte levels is recommended to check for abnormalities, and if symptoms of electrolyte imbalance (e.g., muscle cramps, weakness, confusion) occur, immediate consultation with a healthcare provider is necessary. Due to hydrochlorothiazide, skin may become sensitive to sunlight, so exposure to ultraviolet light should be avoided, and new skin lesions should be reported to a doctor. This medication may interact with other drugs, so it is crucial to inform healthcare providers of any other medications being taken, especially potassium supplements or potassium-containing salt substitutes, which should not be taken without medical consultation. Caution is needed while driving or operating machinery due to potential dizziness or drowsiness, especially during the initial doses or when changing doses. There is limited experience with this medication in children and adolescents, hence it is not recommended for them; also, elderly patients may experience adverse reactions more frequently and should be monitored closely. Pregnant and breastfeeding women should consult a doctor as this medication may pose risks to the fetus and newborn. If breastfeeding, it is advisable to either discontinue breastfeeding or stop taking the medication. Overdose may result in symptoms like hypotension and tachycardia, and immediate medical attention should be sought for appropriate treatment. This medication should be stored in its original container and kept in a safe place out of reach of children.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • low back pain
  • dizziness
Show 130 more
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
  • skin desquamation
  • hemolysis
  • chest pain
  • facial swelling
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • secondary atrioventricular block
  • anorexia
  • constipation
  • toothache
  • dry mouth
  • indigestion
  • flatulence
  • gastritis
  • vomiting
  • malaise
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • neuroirritability
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disorders
  • drowsiness
  • tremors
  • dizziness
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • skin dryness
  • petechiae
  • erythema
  • flushing
  • phototoxic reactions
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • vision impairment
  • taste disturbances
  • tinnitus
  • erectile dysfunction
  • nocturia
  • polyuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsions
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • hemolytic anemia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • fever
  • pneumonia
  • pulmonary edema
  • hyperglycemia
  • diabetes
  • hyperuricemia
  • muscle spasms
  • agitation
  • renal failure
  • renal dysfunction
  • interstitial nephritis
  • skin and mucous membrane syndrome
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute angle-closure glaucoma
  • thrombocytopenia
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • dry cough
  • erythema multiforme
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that does not allow light in. It should also be kept in a sealed container to avoid contact with air, and storage temperature should maintain room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

10 tablets/blister x 3, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.